UH3OD035521
Cooperative Agreement
Overview
Grant Description
Childhood allergy and the neonatal environment in St Louis (CANOE-STL) and the impact of wheezing illnesses on neurocognitive development of preschool children.
Wheezing during preschool years is a common occurrence [1] causing significant healthcare burden [2] with frequent unscheduled physician visits, ED visits, hospitalizations, and treatment with inhaled and systemic corticosteroids along with other medications.
Recurrent wheezing is often the antecedent to asthma, one of the most common chronic diseases of childhood.
Though there is evidence of significant neurocognitive problems in children with other chronic health conditions such as oncological diseases, diabetes, heart disease, sickle cell, and traumatic brain injury [3], the impact of recurrent wheezing illnesses and associated treatment on the neurocognitive and emotional development of infants and preschool children has not been fully characterized.
The ECHO cohort study has been collecting neurodevelopmental measures in children after the late preschool years; however, critical neurodevelopmental trajectories occur in early infancy [4].
Data suggest that these trajectories can be affected by pre-natal conditions, socioeconomic status, stress, disease severity, and/or medication use.
A recent study, in non-asthmatic patients, showed that the use of systemic corticosteroids, a frequently administered treatment for wheezing illnesses, was associated with changes in brain structure [5].
Building on these findings, our overarching study objective is to understand the association of recurrent wheezing illnesses and its associated treatment on the neurocognitive and emotional development of infants and preschool children.
We plan to address this objective with the following aims:
Wheezing during preschool years is a common occurrence [1] causing significant healthcare burden [2] with frequent unscheduled physician visits, ED visits, hospitalizations, and treatment with inhaled and systemic corticosteroids along with other medications.
Recurrent wheezing is often the antecedent to asthma, one of the most common chronic diseases of childhood.
Though there is evidence of significant neurocognitive problems in children with other chronic health conditions such as oncological diseases, diabetes, heart disease, sickle cell, and traumatic brain injury [3], the impact of recurrent wheezing illnesses and associated treatment on the neurocognitive and emotional development of infants and preschool children has not been fully characterized.
The ECHO cohort study has been collecting neurodevelopmental measures in children after the late preschool years; however, critical neurodevelopmental trajectories occur in early infancy [4].
Data suggest that these trajectories can be affected by pre-natal conditions, socioeconomic status, stress, disease severity, and/or medication use.
A recent study, in non-asthmatic patients, showed that the use of systemic corticosteroids, a frequently administered treatment for wheezing illnesses, was associated with changes in brain structure [5].
Building on these findings, our overarching study objective is to understand the association of recurrent wheezing illnesses and its associated treatment on the neurocognitive and emotional development of infants and preschool children.
We plan to address this objective with the following aims:
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Place of Performance
Saint Louis,
Missouri
631101010
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 105% from $1,488,322 to $3,044,252.
Washington University was awarded
Neurocognitive Impact of Wheezing Illnesses in Preschoolers (NIWI)
Cooperative Agreement UH3OD035521
worth $3,044,252
from the National Institute of Allergy and Infectious Diseases in September 2023 with work to be completed primarily in Saint Louis Missouri United States.
The grant
has a duration of 6 years 8 months and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Pregnancy and Pediatric Cohort Study Sites. Clinical Trial Not Allowed (UG3/UH3).
Status
(Ongoing)
Last Modified 6/22/26
Period of Performance
9/1/23
Start Date
5/31/30
End Date
Funding Split
$3.0M
Federal Obligation
$0.0
Non-Federal Obligation
$3.0M
Total Obligated
Activity Timeline
Transaction History
Modifications to UH3OD035521
Additional Detail
Award ID FAIN
UH3OD035521
SAI Number
UH3OD035521-3913561355
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75AGNA NIH AGGREGATE FINANCIAL ASSISTANCE DATA AWARDING OFFICE
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
L6NFUM28LQM5
Awardee CAGE
2B003
Performance District
MO-01
Senators
Joshua Hawley
Eric Schmitt
Eric Schmitt
Modified: 6/22/26